SCANCELL HOLDINGS PLC — Director's Dealing 2013

Jul 23, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8828J

Scancell Holdings Plc

23 July 2013

Scancell Holdings Plc

("Scancell"or the "Company")

Director Shareholdings

The Company has been informed that on 22 July 2013 certain Directors of the Company purchased ordinary shares in the Company as follows:

Director	No. of Shares purchased	Price at which shares purchased	No. of shares held pursuant to transaction (% of ISC following transaction)
David Evans	30,000	31.8 pence	5,130,000 (2.6%)
Kate Cornish-Bowden	45,000	32.0 pence	45,000 (0.02%)

For Further Information:

Scancell Holdings Plc  Dr Richard Goodfellow, Joint CEO  Professor Lindy Durrant, Joint CEO		+ 44 (0) 74 2323 0 497
Cenkos Securities:		+44 (0) 20 7397 8900
Camilla Hume Stephen Keys
FTI Consulting		+44 (0) 20 7831 3113
Simon Conway Mo Noonan

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSEAKXAADSDEFF